(Z)-Isopropyl 7-((1R,2R,3R,5S)-5-Hydroxy-3-((2-Methoxyethoxy)Methoxy)-2-((R)-3-((2-Methoxyethoxy)Methoxy)-5-Phenylpentyl)Cyclopentyl)Hept-5-Enoate置于cerium(III) Chloride Heptahydrate,Sodium Iodide体系中,用 乙腈 用作溶剂,化学反应 2.0H,反应生成拉坦前列素 参考文献: A Novel Process For The Preparation Of Prostaglandins And Intermediates Thereof[fr] Nouveau Procédé De Préparation De Prostaglandines Et De Leurs Intermédiaires 标题: A Novel Process For The Preparation Of Prostaglandins And Intermediates Thereof[fr] Nouveau Procédé De Préparation De Prostaglandines Et De Leurs Intermédiaires 摘要:本发明涉及一种制备公式(k)的前列腺素化合物的新工艺,其中r选自以下组中的一组:C1-C7烷基;C7-C17芳基烷基,其中芳基基团未取代或取代有1-3个取自c1-C6烷基,卤素和cf3的取代基;以及(ch2)nor2,其中n为1-3,R2代表未取代或取代有1-3个取自c1-C6烷基,卤素和cf3的取代基的c6-C10芳基基团;R1选自or3和nhr3,其中r3为c1-C6烷基,H;虚线表示双键或单键.本发明还揭示了新的中间体.
专利号:EP-1721894-A1 优先权日:2005-05-13 标题 :Process for the synthesis of prostaglandin derivatives 发明人:LISI GIUSEPPE 权利人:TECHNOPHARMA SA 摘要:An alternative method for the synthesis of prostaglandin F analogues, in particular, analogues of PGF 2α and specifically for the synthesis of latano-prost, wherein the transformation of the lactone intermediate (5)n ninto the corresponding lactol (7)n nis carried out by treating the lactone intermediate (5) with a silane, preferably polymethylhydrosiloxane (PMHS), in the presence of a titanocene - and preferably titanocene fluoride. n The method enables considerable production economies with respect to the conventional reduction of lactone with diisobutylaluminum hydride (DIBAL-H).
专利号:US-2015031898-A1 优先权日:2012-03-09 标题 :Process for preparation of prostaglandin f2 alpha analogues 发明人:DAMS IWONA; KUTNER ANDRZEJ; CHODYNSKI MICHAL; KRUPA MALGORZATA; PIETRASZEK ANITA; ZEZULA MARTA; CMOCH PIOTR; KOSINSKA MONIKA 权利人:INST FARMACEUTYCZNY 摘要:A convergent synthesis of the prostaglandin F 2α analogues, travoprost and bimatoprost, was developed employing Julia-Lythgoe olefination of the structurally advanced phenylsulfone with an enantiomerically pure aldehyde ω-chain synthon. The novel convergent strategy allows the synthesis of a whole series of prostaglandin analogues of high purity from a common and structurally advanced prostaglandin intermediate.
专利号:US-10100028-B2 优先权日:2013-09-30 标 题:Synthesis routes for prostaglandins and prostaglandin intermediates using metathesis 发明人:YIANNIKOUROS GEORGE PETROS; KALARITIS PANOS; GAMAGE CHAMINDA PRIYAPUSHPA; AREFYEV DENIS VIKTOROVICH 权利人:IRIX PHARMACEUTICALS INC; PATHEON API SERVICES INC 摘要:Methods of synthesizing prostaglandins, prostaglandin analogs and their synthetic intermediates are described. The methods can comprise metal-catalyzed metathesis reactions. Also provided are synthetic intermediates that can be used in the synthesis of the prostaglandins and prostaglandin analogs.
专利号:US-7157590-B2 优先权日:2001-05-31 标题 :Process for the preparation of 17-phenyl-18,19,20-thinor-pgf 2a and its derivatives 发明人:GUTMAN ARIE; NISNEVICH GENNADY; ETINGER MARINA; ZALTZMAN IGOR; YUDOVITCH LEV; PERTSIKOV BORIS 权利人:FINETECH LAB LTD 摘要:The present invention provides a new and effective process for the synthesis of 17-phenyl-18,19,20-trinor-PGF 2α and its derivatives, including the anti-glaucoma drugs Bimatoprost and Latanoprost. The benefit of the present invention rises inter alia from the fact that a major intermediate involved in the synthesis of the above compounds may be isolated from a mixture containing also an undesired isomer, by crystallization. In addition, the undesired isomer may be oxidized to give the starting compound, which is then recycled.
专利号:US-5905091-A 优先权日:1996-07-03 标 题 :Enhancement of skin pigmentation by prostaglandins 发明人:FULLER BRYAN B 权利人:UNIV OKLAHOMA 摘要:A composition comprising a carrier and prostaglandin effective in stimulating synthesis of melanin in a human melanocyte thereby enhancing pigmentation of the human skin and optionally comprising a lysosomotropic agent, a phosphodiesterase inhibitor, and/or methylxanthines, and a method of use of the composition. Use of this composition promotes tanning of the human skin and increases photoprotection from ultraviolet radiation.
专利号:US-7772278-B2 优先权日:1999-03-01 标 题:Nitrosated and nitrosylated prostaglandins, compositions and methods of use 发明人:GARVEY DAVID S; GASTON RICKY D; LETTS L GORDON; DE TEJADA INIGO SAENZ; TAM SANG WILLIAM; WORCEL MANUEL 权利人:NITROMED INC 摘要:The invention describes novel nitrosated and/or nitrosylated prostaglandins, and novel compositions comprising at least one nitrosated and/or nitrosylated prostaglandin, and, optionally, at least one compound that donates, transfers or releases nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor, stimulates endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase, and/or at least one vasoactive agent. The invention also provides novel compositions comprising at least one prostaglandin and at least one S-nitrosothiol compound, and, optionally, at least one vasoactive agent. The prostaglandin is preferably a prostaglandin E 1 compound, more preferably alprostadil, and the S-nitrosothiol compound is preferably S-nitrosoglutathione. The invention also provides methods for treating or preventing sexual dysfunctions in males and females, for enhancing sexual responses in males and females, and for treating or preventing cerebrovascular disorders, cardiovascular disorders, benign prostatic hyperplasia (BPH), glaucoma, peptic ulcers or for inducing abortions.
1: Asrani S, Robin AL, Serle JB, Lewis RA, Usner DW, Kopczynski CC, Heah T; MERCURY-1 Study Group. Netarsudil/Latanoprost Fixed-Dose Combination for Elevated Intraocular Pressure: Three-Month Data from a Randomized Phase 3 Trial. Am J Ophthalmol. 2019 Nov;207:248-257. doi: 10.1016/j.ajo.2019.06.016. Epub 2019 Jun 21. 34(1):72-88. doi: 10.1038/s41433-019-0671-0. Epub 2019 Nov 6. 3: Kurysheva NI. Dolgosrochnoe primenenie latanoprosta v lechenii glaukomy [Long-term use of latanoprost in the treatment of glaucoma]. Vestn Oftalmol. 2020;136(2):125-132. Russian. doi: 10.17116/oftalma2020136021125. 48(6):602-12. doi: 10.1007/s10384-004-0110-y. 220:53-63. doi: 10.1016/j.ajo.2020.06.003. Epub 2020 Jun 10. Erratum in: Am J Ophthalmol. 2021 Aug 27;: 21(1):39-45. doi: 10.1080/14656566.2019.1685499. Epub 2019 Oct 30. 27(3):e72. doi: 10.1097/IJG.0000000000000878. 29(1):55-64. doi: 10.1080/09546634.2017.1330527. Epub 2017 Jun 15. 21(8):305. doi: 10.1208/s12249-020-01863-1. 31(1):1-19. doi: 10.1080/09205063.2019.1669126. Epub 2019 Sep 27.
合成参考文献
参考文献:10.1001/archophthalmol.2011.158 摘要:Digger RC. Response to case study on darkening of a facial skin graft after latanoprost. Arch Ophthalmol. 2011 Jul;129(7):964–5. doi: 10.1001/archophthalmol.2011.158. 摘要:Ammar DA, Kahook MY. Effects of benzalkonium chloride- or polyquad-preserved fixed combination glaucoma medications on human trabecular meshwork cells. Mol Vis. 2011;17():1806–13. 参考文献:10.2165/11539460-000000000-00000 摘要:Iskedjian M, Covert DW, Walker JH. Persistence with prostaglandin agonist use with and without adjunctive therapy for glaucoma patients: a Canadian population-based analysis. Patient. 2011;4(2):133–41. doi: 10.2165/11539460-000000000-00000. 参考文献:10.1089/jop.2011.0003 摘要:Altieri M, Ferrari E. Do Prostaglandin Analogs Affect Eyelid Position and Motility Journal of Ocular Pharmacology and Therapeutics. 2011 Oct;27(5):511–7. doi: 10.1089/jop.2011.0003. 参考文献:10.1007/s12325-011-0043-z 摘要:Scherzer M, Liehneova I, Muñoz Negrete FJ, Schnober D. Travoprost 0.004%/timolol 0.5% fixed combination in patients transitioning from fixed or unfixed bimatoprost 0.03%/timolol 0.5%. Advances in Therapy. 2011 Jul 15;28(8):661. doi: 10.1007/s12325-011-0043-z.